Unknown

Dataset Information

0

Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.

ABSTRACT:

SUBMITTER: Ojha RP 

PROVIDER: S-EPMC6443239 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.

Ojha Rohit P RP   MacDonald Brooke R BR   Chu Tzu-Chun TC   Marcus Julia L JL  

Gastroenterology 20180815 5

Similar Datasets

Unknown Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
| S-EPMC10624323 | biostudies-literature
Unknown Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
| S-EPMC5700296 | biostudies-literature
Unknown Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey.
| S-EPMC7197924 | biostudies-literature
Unknown An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.
| S-EPMC8478781 | biostudies-literature
Unknown Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.
| S-EPMC5840188 | biostudies-literature
Unknown Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
| S-EPMC7491553 | biostudies-literature
Unknown Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
| S-EPMC6034985 | biostudies-literature
Unknown Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
| S-EPMC6303025 | biostudies-literature
Unknown No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
| S-EPMC6276897 | biostudies-literature
Unknown Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
| S-EPMC5663921 | biostudies-literature